Therapeutic options for patients with clonal and idiopathic hypereosinophia.
BACKGROUND
The hypereosinophilic syndrome (HES) comprises a heterogeneous group of disorders characterized by chronic, unexplained hypereosinophilia with organ involvement. The discovery of novel molecular targets has changed the therapeutic paradigm in HES.


OBJECTIVE
This article reviews the current medical management of patients with clonal and idiopathic hypereosinophilia with a particular emphasis on emerging new targeted therapies.


METHODS
The information contained in this review was obtained from public sources such as journals and scientific meeting abstracts. The opinions expressed in this review are solely those of the authors.


CONCLUSIONS
The development of imatinib-resistant mutations in the FIP1L1-PDGFR-alpha kinase domain has spurred the development of an array of new tyrosine kinase inhibitors. Moreover, the elucidation of the role of interleukin-5 in the pathogenesis of the lymphocytic variant of HES and the fact that CD52 is expressed on the surface of eosinophils and T cells have led to the clinical use of monoclonal antibodies such as mepolizumab, reslizumumab, and alemtuzumab for the treatment of different forms of hypereosinophilia.
The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA. aquintas@mdanderson.org
Alfonso
A
Quintás-Cardama
Jorge
J
Cortes
D000465:Algorithms; D000818:Animals; D004802:Eosinophilia / Q000175:diagnosis / Q000378:metabolism; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000276:immunology / Q000378:metabolism / Q000601:surgery / Q000628:therapy*; D007167:Immunotherapy; D033581:Stem Cell Transplantation